PRESS-RELEASE ·Filed May 5, 2026
Press release · FDA
Actionable Insight • Neutral
Routine conference presentation — no material news. Monitor upcoming Phase 2b data for AP01 (MIST trial) as the next catalyst.
Final — all horizons settled through T+60d
AVLN ▲ +3.90% at T+60d
NEUTRAL call +3.90% · α vs SPY +1.84% · entry $27.71 → $28.79
T+1d
0.00%
call 0.00% · α +0.33%
$27.71
settled 6mo ago
T+5d
+7.90%
call +7.90% · α +6.77%
$29.90
settled 6mo ago
T+20d
-4.73%
call -4.73% · α -7.51%
$26.40
settled 5mo ago
T+60d
+3.90%
call +3.90% · α +1.84%
$28.79
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Avalyn Pharma announced two presentations at the ATS 2026 conference, including a usability study of its AP01 nebulizer and research on IPF patient experiences. The presentations are routine clinical updates with no new efficacy or safety data, and no material impact on the stock.
Key Facts
- Two poster presentations at ATS 2026 (May 15-20) on AP01 nebulizer usability and IPF patient perspectives.
- CEO Lyn Baranowski emphasized patient input in development.
- No new clinical data, guidance, or financial information provided.
- Company's pipeline: AP01 (Phase 2b for PPF), AP02 (Phase 2 for IPF), AP03 (preclinical fixed-dose combination).
Financial Impact
No financial impact from this press release.
Risk Factors
- No new data disclosed; pipeline risk remains.
- Clinical trial failures could significantly impact valuation.
- Competition from approved oral therapies (pirfenidone, nintedanib) and other inhaled candidates.
Market Snapshot
Exchange
Nasdaq
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288206 |
17 reports for AVLN
67% Hit rate @ T+5 Went positive at some point 3 of 3 best @ T+1▲ +2.62%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | Press Release | $31.62 $28.32 | ▼ −10.44% | ▼ −9.42% | $26.04 (−17.65%) |
Aug 16, 2026 10w ago | Institutional Cluster | $38.25 $37.69 | ▼ −1.46% | ▼ −0.27% | $26.04 (−31.92%) |
Aug 12, 2026 10w ago | 8-K | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $26.04 (−30.34%) |
Aug 12, 2026 10w ago | Press Release | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $26.04 (−30.34%) |
Jun 17, 2026 18w ago | 8-K | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $26.04 (−11.16%) |
Jun 17, 2026 18w ago | Press Release | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $26.04 (−11.16%) |
Jun 3, 2026 20w ago | 8-K | $26.40 $28.53 | ▲ +8.07% | ▲ +11.89% | $26.04 (−1.36%) |
May 5, 2026 24w ago | Press Release | $27.71 $29.90 | ▲ +7.90% | ▲ +6.77% | $26.04 (−6.03%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $26.04 (−10.42%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $26.04 (−10.42%) |
Showing 10 of 17
US Market Status
Market Closed — Opens Wed (11h 54m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers